Stewart Z A, Leach S D, Pietenpol J A
Departments of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
Mol Cell Biol. 1999 Jan;19(1):205-15. doi: 10.1128/MCB.19.1.205.
During a normal cell cycle, entry into S phase is dependent on completion of mitosis and subsequent activation of cyclin-dependent kinases (Cdks) in G1. These events are monitored by checkpoint pathways. Recent studies and data presented herein show that after treatment with microtubule inhibitors (MTIs), cells deficient in the Cdk inhibitor p21(Waf1/Cip1) enter S phase with a >/=4N DNA content, a process known as endoreduplication, which results in polyploidy. To determine how p21 prevents MTI-induced endoreduplication, the G1/S and G2/M checkpoint pathways were examined in two isogenic cell systems: HCT116 p21(+/+) and p21(-/-) cells and H1299 cells containing an inducible p21 expression vector (HIp21). Both HCT116 p21(-/-) cells and noninduced HIp21 cells endoreduplicated after MTI treatment. Analysis of G1-phase Cdk activities demonstrated that the induction of p21 inhibited endoreduplication through direct cyclin E/Cdk2 regulation. The kinetics of p21 inhibition of cyclin E/Cdk2 activity and binding to proliferating-cell nuclear antigen in HCT116 p21(+/+) cells paralleled the onset of endoreduplication in HCT116 p21(-/-) cells. In contrast, loss of p21 did not lead to deregulated cyclin D1-dependent kinase activities, nor did p21 directly regulate cyclin B1/Cdc2 activity. Furthermore, we show that MTI-induced endoreduplication in p53-deficient HIp21 cells was due to levels of p21 protein below a threshold required for negative regulation of cyclin E/Cdk2, since ectopic expression of p21 restored cyclin E/Cdk2 regulation and prevented endoreduplication. Based on these findings, we propose that p21 plays an integral role in the checkpoint pathways that restrain normal cells from entering S phase after aberrant mitotic exit due to defects in microtubule dynamics.
在正常细胞周期中,进入S期取决于有丝分裂的完成以及随后G1期细胞周期蛋白依赖性激酶(Cdks)的激活。这些事件由检查点通路监测。本文呈现的最新研究和数据表明,在用微管抑制剂(MTIs)处理后,缺乏细胞周期蛋白依赖性激酶抑制剂p21(Waf1/Cip1)的细胞会以≥4N的DNA含量进入S期,这一过程称为核内复制,会导致多倍体形成。为了确定p21如何防止MTI诱导的核内复制,在两个同基因细胞系统中检测了G1/S和G2/M检查点通路:HCT116 p21(+/+)和p21(-/-)细胞以及含有可诱导p21表达载体(HIp21)的H1299细胞。MTI处理后,HCT116 p21(-/-)细胞和未诱导的HIp21细胞都发生了核内复制。对G1期Cdk活性的分析表明,p21的诱导通过直接调节细胞周期蛋白E/Cdk2抑制了核内复制。HCT116 p21(+/+)细胞中p21抑制细胞周期蛋白E/Cdk2活性以及与增殖细胞核抗原结合的动力学与HCT116 p21(-/-)细胞中核内复制的开始情况相似。相反,p21的缺失并未导致细胞周期蛋白D1依赖性激酶活性失控,p21也没有直接调节细胞周期蛋白B1/Cdc2活性。此外,我们发现p53缺陷的HIp21细胞中MTI诱导的核内复制是由于p21蛋白水平低于负调节细胞周期蛋白E/Cdk2所需的阈值,因为p21的异位表达恢复了细胞周期蛋白E/Cdk2的调节并防止了核内复制。基于这些发现,我们提出p21在检查点通路中起着不可或缺的作用,该通路可抑制正常细胞在由于微管动力学缺陷导致异常有丝分裂退出后进入S期。